TITLE

The War on Cancer

AUTHOR(S)
Moss, Ralph W.
PUB. DATE
November 2006
SOURCE
Townsend Letter;Nov2006, Issue 280, p48
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the approval of drug Gemzar by the Food and Drug Administration for the treatment of recurrent ovarian cancer in the U.S. Gemzar drug was already the second best-selling drug of Eli Lilly and it was approved in the US to treat lung, pancreatic, and breast cancer and it was also approved in some countries outside the US to treat the ovarian cancer. It was noted that even without the FDA approval, the doctors could still prescribe Gemzar for the advanced ovarian cancer.
ACCESSION #
22875175

 

Related Articles

  • Raloxifene Prevails in STAR Trial, May Face Easier Road to Acceptance Than Previous Drugs. Vastag, Brian // JNCI: Journal of the National Cancer Institute;6/7/2006, Vol. 98 Issue 11, p733 

    The article reports on the study designed to compare the effectiveness of tamoxifen and raloxifene to prevent breast cancer in the U.S. Larry Wickerham, associate director of the National Surgical Adjuvant Breast and Bowel Project, announced that the winner in the study is raloxifene. The result...

  • Eli Lilly: Gemzar gets the go-ahead.  // PharmaWatch: Cancer;June 2004, Vol. 3 Issue 6, p21 

    Announces that the U.S. Food and Drug Administration has approved a Gemzar-Taxol combination as a first-line treatment for patients with metastatic breast cancer. Approval of the combination in several other countries.

  • Eli Lilly lung cancer drug gains FDA approval.  // PharmaWatch: Cancer;October 2004, Vol. 3 Issue 10, p10 

    This article reports that Eli Lilly & Co. lung cancer drug gains FDA approval. Indianapolis-based Eli Lilly has revealed the FDA approval of Alimta to treat the most common form of lung cancer. Alimta secured accelerated approval for the treatment of non-small cell lung cancer after data...

  • Eli Lilly: closer to expanding Evista brand.  // PharmaWatch: Cancer;Sep2007, Vol. 6 Issue 9, p9 

    The author reflects on the approval of the U.S. Food and Drug Administration (FDA) concerning the extension of the approved indications for Eli Lilly Co.'s Evista. The author stresses that despite controversy surrounding the drug, the extra indication would boost Evista brand revenue and...

  • Product Update. Burger, Valerie // Oncology Nursing Forum;Jan2008, Vol. 35 Issue 1, p137 

    The article presents updates on cancer treatment. The U.S. Food and Drug Administration (FDA) approval of GeneSearchâ„¢ Breast Lymph Node (BLN) Assay (Veridex) marks the first molecularly based technology to determine whether the disease is node-positive. The FDA approved raloxifene...

  • FDA Approves Gemzar. Moss, Ralph // Gerson Healing Newsletter;Mar/Apr2007, Vol. 22 Issue 2, p1 

    The article reports on the approval of the drug Gemzar, a treatment of recurring ovarian cancer, by the U.S. Food and Drug Administration (FDA). Gemzar is produced by Eli Lilly & Co., and has been approved to be used in the treatment of lung, pancreatic, and breast cancer. According to sources,...

  • Companion diagnostics for targeted cancer drugs - clinical and regulatory aspects. Olsen, Dana; Trøst Jørgensen, Jan // Frontiers in Oncology;May2014, Vol. 4, p1 

    Companion diagnostics (CDx) holds the promise of improving the predictability of the oncology drug development process and become an important tool for the oncologist in relation to the choice of treatment for the individual patient. A number of drug-diagnostic co-development programs have...

  • It's the `fast track' for a new cancer drug.  // Medical Update;Apr95, Vol. 18 Issue 10, p1 

    Reports that the Food and Drug Administration gave its `fast track' approval to Eli Lilly and Co.'s anticancer drug, Gemzar. Eli Lilly's provision of free Gemzar to patients with pancreatic cancer who are not suitable for surgery; Pathophysiology of cancer; Mechanism of action and physiological...

  • New FDA cancer rules expected to boost Lilly.  // Indianapolis Business Journal;04/08/96, Vol. 17 Issue 3, p26 

    Reports on the implications of the US Food and Drug Administration's (FDA) plan to allow drug companies to market drugs after showing only that they provide an apparent benefit. Impact of the rule on Eli Lilly & Co. and other cancer-research firms; Need for the FDA to act on cancer applications...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics